Chengfei Pu

726 total citations
19 papers, 277 citations indexed

About

Chengfei Pu is a scholar working on Oncology, Molecular Biology and Genetics. According to data from OpenAlex, Chengfei Pu has authored 19 papers receiving a total of 277 indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Oncology, 4 papers in Molecular Biology and 4 papers in Genetics. Recurrent topics in Chengfei Pu's work include CAR-T cell therapy research (17 papers), Cancer Research and Treatments (4 papers) and Virus-based gene therapy research (3 papers). Chengfei Pu is often cited by papers focused on CAR-T cell therapy research (17 papers), Cancer Research and Treatments (4 papers) and Virus-based gene therapy research (3 papers). Chengfei Pu collaborates with scholars based in China, United Kingdom and Israel. Chengfei Pu's co-authors include Lei Xiao, Xuexiao Jin, Yu Jiang, Kaixiang Zhu, Qin Xu, Linrong Lu, Cheng Lu, Yongmei Han, Jinping Wang and Guoqing Wei and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer Research.

In The Last Decade

Chengfei Pu

18 papers receiving 271 citations

Peers

Chengfei Pu

ONCOL

IMMUN

GENET

Tiina Hannunen Finland

Daniel Atar Germany

Alexandria Van Scoyk United States

Julia Riewaldt Germany

Mike Essl Germany

Steven Tsai United States

Xinjie Xu United States

Déborah Meyran Australia

Tianning Gu China

Anaïs Jiménez-Reinoso Spain

Tiina Hannunen Finland

Chengfei Pu

139 ×0.7

ONCOL

125 ×1.3

IMMUN

100 ×1.1

46 ×0.8

GENET

13 ×0.4

Citations per year, relative to Chengfei Pu Chengfei Pu (= 1×) peers Tiina Hannunen

Countries citing papers authored by Chengfei Pu

Since Specialization

Citations

This map shows the geographic impact of Chengfei Pu's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Chengfei Pu with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Chengfei Pu more than expected).

Fields of papers citing papers by Chengfei Pu

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Chengfei Pu. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Chengfei Pu. The network helps show where Chengfei Pu may publish in the future.

Co-authorship network of co-authors of Chengfei Pu

This figure shows the co-authorship network connecting the top 25 collaborators of Chengfei Pu. A scholar is included among the top collaborators of Chengfei Pu based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Chengfei Pu. Chengfei Pu is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

19 of 19 papers shown

Pu, Chengfei, Xianyang Jiang, Xiaogang Shen, et al.. (2025). Novel PAP-targeted CAR-T therapy enhances antitumor efficacy through CoupledCAR approach. Journal for ImmunoTherapy of Cancer. 13(5). e011238–e011238. 1 indexed citations

Zhang, Hongbo, Bin Yang, Chengfei Pu, et al.. (2025). Synergistic Drivers of Vegetation Dynamics in a Fragile High-Altitude Basin of the Tibetan Plateau Using General Regression Neural Network and Geographical Detector. Remote Sensing. 17(11). 1829–1829. 1 indexed citations

Chen, Naifei, Chengfei Pu, Lingling Zhao, et al.. (2023). A phase 1 dose escalation study of GCC19CART: A novel coupled CAR therapy for patients with metastatic colorectal cancer.. Journal of Clinical Oncology. 41(16_suppl). 3547–3547. 1 indexed citations

Cui, Jiuwei, Naifei Chen, Chengfei Pu, et al.. (2022). A phase 1 dose-escalation study of GCC19 CART a novel coupled CAR therapy for subjects with metastatic colorectal cancer.. Journal of Clinical Oncology. 40(16_suppl). 3582–3582. 5 indexed citations

Xiao, Lei, Xingchen Liu, Keshu Zhou, et al.. (2021). CoupledCAR technology for treating thyroid cancer.. Journal of Clinical Oncology. 39(15_suppl). e14507–e14507. 1 indexed citations

Jin, Xuexiao, Qin Xu, Chengfei Pu, et al.. (2020). Therapeutic efficacy of anti-CD19 CAR-T cells in a mouse model of systemic lupus erythematosus. Cellular and Molecular Immunology. 18(8). 1896–1903. 135 indexed citations

Pu, Chengfei, Cheng Lu, Hang Yang, et al.. (2020). Abstract LB-380: Novel coupledCARTMtechnology for treating colorectal cancer. Cancer Research. 80(16_Supplement). LB–380. 1 indexed citations

Xiao, Lei, Song Li, Chengfei Pu, et al.. (2020). Novel CoupledCAR technology for treating colorectal cancer.. Journal of Clinical Oncology. 38(15_suppl). e15035–e15035. 1 indexed citations

Pu, Chengfei, Yang Su, Lina Jin, et al.. (2020). Dominant negative PD1 armored CART cells to induce remission in relapsed or refractory non-Hodgkin lymphoma (NHL) patients.. Journal of Clinical Oncology. 38(15_suppl). e15028–e15028. 2 indexed citations

10.

Xiao, Lei, Chengfei Pu, Xinyi Yang, et al.. (2020). Novel CoupledCARTM Technology for Treating Colorectal Cancer. Blood. 136(Supplement 1). 54–54. 1 indexed citations

11.

Liu, Xingchen, Keshu Zhou, Yong Huang, et al.. (2020). 400 CoupledCARTM technology for treating thyroid cancer. Regular and Young Investigator Award Abstracts. A243–A244. 1 indexed citations

12.

Wen, Hairuo, Zhe Qu, Chengfei Pu, et al.. (2019). Preclinical safety evaluation of chimeric antigen receptor-modified T cells against CD19 in NSG mice. Annals of Translational Medicine. 7(23). 735–735. 19 indexed citations

13.

Chen, Tong, Yan Yuan, Chengfei Pu, et al.. (2019). Dominant-negative PD1-armored CART cells induce remission in refractory diffuse large B-cell lymphoma (DLBCL) patients.. Journal of Clinical Oncology. 37(15_suppl). e19028–e19028. 7 indexed citations

14.

Hu, Yongxian, Jiasheng Wang, Chengfei Pu, et al.. (2018). Delayed Terminal Ileal Perforation in a Relapsed/Refractory B-Cell Lymphoma Patient with Rapid Remission Following Chimeric Antigen Receptor T-Cell Therapy. Cancer Research and Treatment. 50(4). 1462–1466. 10 indexed citations

15.

Wei, Guoqing, Yongxian Hu, Chengfei Pu, et al.. (2018). CD19 targeted CAR-T therapy versus chemotherapy in re-induction treatment of refractory/relapsed acute lymphoblastic leukemia: results of a case-controlled study. Annals of Hematology. 97(5). 781–789. 21 indexed citations

16.

Hu, Yongxian, Chengfei Pu, Haofei Zhang, et al.. (2017). Successful chimeric Ag receptor modified T cell therapy for isolated testicular relapse after hematopoietic cell transplantation in an acute lymphoblastic leukemia patient. Bone Marrow Transplantation. 52(7). 1065–1067. 7 indexed citations

17.

Wu, Zhao, Zhi Liu, Shuang Liu, et al.. (2016). Anti-CD19 chimeric antigen receptor T-cell therapy for adult Philadelphia chromosome-positive acute lymphoblastic leukemia. Medicine. 95(51). e5676–e5676. 19 indexed citations

18.

Zhang, Chen‐Song, Qi Liu, Mengqi Li, et al.. (2015). RHOBTB3 promotes proteasomal degradation of HIFα through facilitating hydroxylation and suppresses the Warburg effect. Cell Research. 25(9). 1025–1042. 44 indexed citations

19.

Xiao, Lei, Zhao Wu, Yi Luo, et al.. (2015). CD19 CAR-T Cells Administered after High-Dose Cyclophosphamide Chemotherapy Induce Rapid Remissions of Chemotherapy-Refractory Acute B-Cell Leukemia with High Tumor Burden. Blood. 126(23). 4909–4909.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact